Ohmx completed its Series A preferred stock financing in 2009, raising $5.1 million.  The proceeds from the initial financing are being used to complete Series A milestones including development of the first working prototype, feasibility and applicability in eight clinical diagnostic assays and four industrial application assays, a clinical pilot study, securing intellectual property licenses and developing Ohmx's own patent portfolio. 

The Company has secured bridge financing and is planning to close a Series B round by December of 2010. Series B milestones include assay and instrument development under design control, clinical testing, and regulatory submission of our first 510(k) product.

For more information, please contact Ohmx investor relations: investor@ohmx.com

[ back to top ]